November 18, 2026 · Journal of pain and symptom management · DOI: 10.1016/j.jpainsymman.2026.11.008

Divergent Mechanisms of Reward Reduction in Buprenorphine and Methadone: Implications for Opioid Selection in Cancer Pain with Elevated Misuse Liability.

Listen to this summary

This paper compares how buprenorphine and methadone reduce opioid reward, asking whether their effects arise from the same mechanism. The author argues they differ: buprenorphine competitively blunts the reward of a co-administered full agonist, whereas methadone's reduced reward is an intrinsic, receptor-selective property of methadone itself that does not transfer to a second agonist. These distinctions are presented as relevant to selecting opioids for cancer pain in patients with elevated misuse liability.

Mellar P Davis

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play